Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help. In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them.• Do cholinesterase inhibitors really work?• What should clinicians know about lecanemab and donanemab before referring patients?• How much benefit should we expect and for how long?• When should you deprescribe dementia medications?🔹Sponsor: Caraway’s cookware set is a favorite for a reason.For 10% off, go to Carawayhome.com/CoreIM or use code CoreIM at checkout.🔹Transcript and Shownotes02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia?09:41 | Deep Dive 2: Prescribing medications for cognitive decline29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline35:46 | Deep Dive 4: Planning for an uncertain futureTags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistantFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Our Sponsors:* Check out FIGS and use our code FIGSRX for a great deal: https://wearfigs.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related